About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01104259

Phase I Study of ABT-888 (veliparib) in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer

Study identifier: NCT01104259
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbott)

Eligibility:

  • Patients with recurrent and/or metastatic triple negative breast cancer or BRCA1 or BRCA2 mutation and recurrent and/or metastatic breast cancer
  • Subjects must have measurable disease, defined as at least one lesion that can be measured in at least one dimension; this includes measurable (bi-dimensional) chest wall disease and/or cutaneous metastatic lesions at least 10 mm

Type of study:

Phase I study

Treatment:

Patients receive oral ABT-888 twice daily on days 1-14 (days 0-13 of course 1 only). Patients also receive cisplatin IV and vinorelbine IV on days 1 and 8. Treatment repeats every 21 days for 6- 10 courses in the absence of disease progression or unacceptable toxicity. Treatment with ABT-888 alone may continue in the absence of disease progression or unacceptable toxicity.

Study site:

Washington

Fred Hutchinson Cancer Research Center/University of Washington Cancer
Consortium      
Seattle, Washington, 98109
Contact: Phase I Program 206-288-7551 phase1@u.washington.edu       
Principal Investigator: John Thompson

 

Page updated 07/08/13

Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org